Similar effects were found using a pegylated leptin peptide receptor antagonist (PEG-LPrA2) for inhibition of leptin signaling in lean and diet-obesity-induced mice treated with DMBA [Gonzalez-Perez, Manuscript in preparation]. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.